Literature DB >> 22537539

The role of hypoxia-inducible factor-1α and -2α in androgen insensitive prostate cancer cells.

Chang Wook Jeong1, Cheol Yong Yoon, Seong Jin Jeong, Sung Kyu Hong, Seok-Soo Byun, Cheol Kwak, Sang Eun Lee.   

Abstract

OBJECTIVES: The aim of this study was to investigate the effects of induction and knocking down of hypoxia-inducible factor (HIF)-1α and/or -2α on tumor biology in androgen insensitive prostate cancer cell lines.
MATERIALS AND METHODS: The induction patterns of HIF-1α and -2α after treatment with ZnSO4 were evaluated in PC3 and DU145 cells. Both cell lines were transfected with siRNA targeted against HIF-1α and/or -2α, and the expression patterns of these 2 HIF isoforms were examined. We next performed cell counting Kit-8 (CCK-8) assays and matrigel invasion assays. Potential additive effects of HIF blockade to chemotherapy (docetaxel) or target agents (sunitinib and sorafenib) were examined. In addition, gene expression changes were determined in ZnSO4-treated DU145 cells using Western blotting.
RESULTS: ZnSO4 affected the expression of HIF in a dose-dependent manner. HIF expression was increased within the first 3 hours but then decreased. Cells in which HIF-1α and/or -2α had been knocked down using siRNA showed decreased cell viability. Invasion abilities were increased by ZnSO4 treatment in both cell lines overexpressing HIF. However, invasion potencies were decreased in response to treatment with HIF siRNAs. Blocking HIF prominently augmented the antitumor effects of target agents. The underlying mechanism could be associated with p21, cMET, IGF-1, and GLUT-1.
CONCLUSIONS: Our results demonstrate that HIF-1α and -2α are important for cell proliferation and invasion ability in prostate cancer. Together, our results indicate that combinations of target agents with HIF knockdown may represent a promising strategy for the treatment of prostate cancer.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Hypoxia-inducible factor; Prostate cancer; Zinc; siRNA

Mesh:

Substances:

Year:  2012        PMID: 22537539     DOI: 10.1016/j.urolonc.2012.03.022

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  6 in total

1.  Spheroid culture of LuCaP 147 as an authentic preclinical model of prostate cancer subtype with SPOP mutation and hypermutator phenotype.

Authors:  Matthias Saar; Hongjuan Zhao; Rosalie Nolley; Sarah R Young; Ilsa Coleman; Peter S Nelson; Robert L Vessella; Donna M Peehl
Journal:  Cancer Lett       Date:  2014-07-03       Impact factor: 8.679

2.  Zinc ion dyshomeostasis increases resistance of prostate cancer cells to oxidative stress via upregulation of HIF1α.

Authors:  David Wetherell; Graham S Baldwin; Arthur Shulkes; Damien Bolton; Joseph Ischia; Oneel Patel
Journal:  Oncotarget       Date:  2018-01-03

3.  PKM2 and HIF-1α regulation in prostate cancer cell lines.

Authors:  Diya Hasan; Elisabetta Gamen; Nafez Abu Tarboush; Yazan Ismail; Oleg Pak; Belal Azab
Journal:  PLoS One       Date:  2018-09-14       Impact factor: 3.240

4.  Hypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cells.

Authors:  Murielle Mimeault; Surinder K Batra
Journal:  J Cell Mol Med       Date:  2013-01-10       Impact factor: 5.310

5.  Chemical biology drug sensitivity screen identifies sunitinib as synergistic agent with disulfiram in prostate cancer cells.

Authors:  Kirsi Ketola; Olli Kallioniemi; Kristiina Iljin
Journal:  PLoS One       Date:  2012-12-12       Impact factor: 3.240

Review 6.  Cellular rewiring in lethal prostate cancer: the architect of drug resistance.

Authors:  Marc Carceles-Cordon; W Kevin Kelly; Leonard Gomella; Karen E Knudsen; Veronica Rodriguez-Bravo; Josep Domingo-Domenech
Journal:  Nat Rev Urol       Date:  2020-03-16       Impact factor: 14.432

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.